Treatment of isolated pediatric optic nerve glioma: A nationwide retrospective cohort study and systematic literature review on visual and radiological outcome.
MRI
children
low grade glioma
optic nerve glioma
response assessment
visual function
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
08 Oct 2024
08 Oct 2024
Historique:
revised:
02
09
2024
received:
24
06
2024
accepted:
14
09
2024
medline:
9
10
2024
pubmed:
9
10
2024
entrez:
9
10
2024
Statut:
aheadofprint
Résumé
Progressive isolated optic nerve glioma (ONG) in children is a rare disease, treated with various modalities. A global treatment consensus is not available. We conducted a national retrospective multicenter cohort study (1995-2020) to investigate how different treatment strategies impact outcome for ONG in children, by assessing treatment responses to systemic anticancer therapy (SAT), surgery, and radiotherapy for ONG. The primary endpoints included changes in best-corrected visual acuity (BCVA) and tumor volume (TV) on MRI, both evaluated at the start and end of therapy and at long-term follow up. A total of 21 ONGs (20 patients) received SAT (n = 14 (66.7%)), surgery (n = 4 (19.0%)), and radiotherapy (n = 3 (14.3%)). After SAT BCVA stabilized or improved in 66.6% (n = 4) and the TV decreased by a median of 45.1% (range: -88.6% to +31.5%) (n = 13). Before resection two eyes were already blind. After resection BCVA decreased to blindness in one eye. In total all four eyes were blind after resection. After first-line RT BCVA decreased in 66.7% of ONG to counting fingers or less, TV increased <3 months after RT by a median of 47.3% (range: -42.8% to +245.1%) (n = 3), followed by a long-term decrease of 94.4 and 13.8% (n = 2), respectively. SAT appears to be the preferred modality for progressive ONG in case of potential rescue of visual functions. Complete resection of ONG appears effective to reduce proptosis in case of preexisting blindness. The use of radiotherapy requires careful consideration due to the risk of severe visual impairment and secondary disease.
Sections du résumé
BACKGROUND
BACKGROUND
Progressive isolated optic nerve glioma (ONG) in children is a rare disease, treated with various modalities. A global treatment consensus is not available.
METHODS
METHODS
We conducted a national retrospective multicenter cohort study (1995-2020) to investigate how different treatment strategies impact outcome for ONG in children, by assessing treatment responses to systemic anticancer therapy (SAT), surgery, and radiotherapy for ONG. The primary endpoints included changes in best-corrected visual acuity (BCVA) and tumor volume (TV) on MRI, both evaluated at the start and end of therapy and at long-term follow up.
RESULTS
RESULTS
A total of 21 ONGs (20 patients) received SAT (n = 14 (66.7%)), surgery (n = 4 (19.0%)), and radiotherapy (n = 3 (14.3%)). After SAT BCVA stabilized or improved in 66.6% (n = 4) and the TV decreased by a median of 45.1% (range: -88.6% to +31.5%) (n = 13). Before resection two eyes were already blind. After resection BCVA decreased to blindness in one eye. In total all four eyes were blind after resection. After first-line RT BCVA decreased in 66.7% of ONG to counting fingers or less, TV increased <3 months after RT by a median of 47.3% (range: -42.8% to +245.1%) (n = 3), followed by a long-term decrease of 94.4 and 13.8% (n = 2), respectively.
CONCLUSION
CONCLUSIONS
SAT appears to be the preferred modality for progressive ONG in case of potential rescue of visual functions. Complete resection of ONG appears effective to reduce proptosis in case of preexisting blindness. The use of radiotherapy requires careful consideration due to the risk of severe visual impairment and secondary disease.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e31358Subventions
Organisme : ODAS Foundation
ID : 2019-01
Informations de copyright
© 2024 The Author(s). Pediatric Blood & Cancer published by Wiley Periodicals LLC.
Références
Bø HK, Solheim O, Jakola AS, Kvistad KA, Reinertsen I, Berntsen EM. Intra‐rater variability in low‐grade glioma segmentation. J Neurooncol. 2017;131(2):393‐402.
Hamideh D, Hoehn ME, Harreld JH, Klimo PD, Gajjar A, Qaddoumi I. Isolated optic nerve glioma in children with and without neurofibromatosis: retrospective characterization and analysis of outcomes. J Child Neurol. 2018;33(6):375‐382.
Shields JA, Bakewell B, Augsburger JJ, Flanagan JC. Classification and incidence of space‐occupying lesions of the orbit. A survey of 645 biopsies. Arch Ophthalmol. 1984;102(11):1606‐1611.
Dutton JJ. Gliomas of the anterior visual pathway. Surv Ophthalmol. 1994;38(5):427‐452.
Nicolin G, Parkin P, Mabbott D, et al. Natural history and outcome of optic pathway gliomas in children. Pediatr Blood Cancer. 2009;53(7):1231‐1237.
Shofty B, Ben‐Sira L, Kesler A, et al. Isolated optic nerve gliomas: a multicenter historical cohort study. J Neurosurg Pediatr. 2017;20(6):549‐555.
Packer RJ, Lange B, Ater J, et al. Carboplatin and vincristine for recurrent and newly diagnosed low‐grade gliomas of childhood. J Clin Oncol. 1993;11(5):850‐856.
Revere KE, Katowitz WR, Katowitz JA, Rorke‐Adams L, Fisher MJ, Liu GT. Childhood optic nerve glioma: vision loss due to biopsy. Ophthal Plast Reconstr Surg. 2017;33(3S):S107‐S109. Suppl 1.
Laithier V, Grill J, Le Deley MC, et al. Progression‐free survival in children with optic pathway tumors: dependence on age and the quality of the response to chemotherapy–results of the first French prospective study for the French Society of Pediatric Oncology. J Clin Oncol. 2003;21(24):4572‐4578.
Gnekow AK, Walker DA, Kandels D, et al. A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18‐month treatment programme for childhood (≤16 years) low grade glioma—a final report. Eur J Cancer. 2017;81:206‐225.
Bennebroek CAM, Wijninga LE, Limpens J, Schouten‐van Meeteren AYN, Saeed P. Impact of systemic anticancer therapy in pediatric optic pathway glioma on visual function: a systematic review. PLoS One. 2021;16(10):e0258548.
Institute JB, Joanna Briggs Institute Critical Appraisal (JBI‐CA) tool for case series. 2017. Accessed 30 November 2023. https://jbiglobal/sites/default/files/2019‐05/JBI_Critical_Appraisal‐Checklist_for_Case_Series2017_0pdf
Moussa G, Bassilious K, Mathews N. A novel excel sheet conversion tool from Snellen fraction to LogMAR including ‘counting fingers’, ‘hand movement’, ‘light perception’ and ‘no light perception’ and focused review of literature of low visual acuity reference values. Acta Ophthalmol. 2021;99(6):e963‐e965.
World Health Organization. International Statistical Classification of Diseases and Related Health Problems: 10th Revision. ICD‐10 Version 2019. Accessed 30 November 2023. https://icd.who.int/browse10/2019/en#/H54.9
Bennebroek CAM, van Zwol J, Porro GL, et al. Impact of bevacizumab on visual function, tumor size, and toxicity in pediatric progressive optic pathway glioma: a retrospective nationwide multicentre study. Cancers. 2022;14(24):6087.
Taylor T, Jaspan T, Milano G, et al. Radiological classification of optic pathway gliomas: experience of a modified functional classification system. Br J Radiol. 2008;81(970):761‐766.
Gnekow AK, Kandels D, Tilburg CV, et al. SIOP‐E‐BTG and GPOH guidelines for diagnosis and treatment of children and adolescents with low grade glioma. Klin Padiatr. 2019;233(3):107‐122.
Koo TK, Li MY. A guideline of selecting and reporting intraclass correlation coefficients for reliability research. J Chiropr Med. 2016;15(2):155‐163.
Tow SL, Chandela S, Miller NR, Avellino AM. Long‐term outcome in children with gliomas of the anterior visual pathway. Pediatr Neurol. 2003;28(4):262‐270.
Chukwueke UN, Wen PY. Use of the Response Assessment in Neuro‐Oncology (RANO) criteria in clinical trials and clinical practice. CNS Oncol. 2019;8(1):Cns28.
Fangusaro J, Witt O, Hernáiz Driever P, et al. Response assessment in paediatric low‐grade glioma: recommendations from the Response Assessment in Pediatric Neuro‐Oncology (RAPNO) working group. Lancet Oncol. 2020;21(6):e305‐e316.
Fisher MJ, Loguidice M, Gutmann DH, et al. Visual outcomes in children with neurofibromatosis type 1‐associated optic pathway glioma following chemotherapy: a multicenter retrospective analysis. Neuro Oncol. 2012;14(6):790‐797.
Falzon K, Drimtzias E, Picton S, Simmons I. Visual outcomes after chemotherapy for optic pathway glioma in children with and without neurofibromatosis type 1: results of the International Society of Paediatric Oncology (SIOP) Low‐Grade Glioma 2004 trial UK cohort. Br J Ophthalmol. 2018;102(10):1367‐1371.
Leone JF, Mitchell P, Kifley A, Rose KA. Normative visual acuity in infants and preschool‐aged children in Sydney. Acta Ophthalmol. 2014;92(7):e521‐e529.
Zipfel J, Tellermann J, Besch D, et al. Surgical management of pre‐chiasmatic intraorbital optic nerve gliomas in children after loss of visual function‐resection from bulbus to chiasm. Children (Basel). 2022;9(4):459.
Zagirov RI, Trunin YY, Serova NK, Pronin IN, Antipina NA, Golanov AV. Hypofractionated stereotactic irradiation for optic nerve glioma. Zh Vopr Neirokhir Im N N Burdenko. 2022;86(5):74‐80.
Lu VM, Welby JP, Laack NN, Mahajan A, Daniels DJ. Pseudoprogression after radiation therapies for low grade glioma in children and adults: a systematic review and meta‐analysis. Radiother Oncol. 2020;142:36‐42.
Nuzzi R, Trossarello M, Bartoncini S, et al. Ocular complications after radiation therapy: an observational study. Clin Ophthalmol. 2020;14:3153‐3166.